版本:
中国

BRIEF-BeiGene presents updated data from Phase 1 study of BTK inhibitor BGB-3111

June 15 BeiGene Ltd:

* Presented updated data from ongoing Phase 1 study of Bruton's tyrosine kinase inhibitor BGB-3111 in patients with Waldenström's macroglobulinemia

* VGPR rate also further supports continued evaluation of BGB-3111 in its global, head-to-head Phase 3 study against ibrutinib in WM

* Says updated Phase 1 data continue to demonstrate that BGB-3111 is well tolerated Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐